Press Releases

13-09-2023

Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients

MORE >

10-08-2023

Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023

MORE >

21-07-2023, 15:21 CEST (Ad hoc press release)

Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.

MORE >

08-06-2023

Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma

MORE >

07-06-2023

ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share. Reorganization of the Executive Board, Supervisory Board and Group Executive Committee.

MORE >

30-05-2023

Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA

MORE >

15-05-2023

Reorganization in the Executive Board of Eckert & Ziegler

MORE >

11-05-2023

Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023

MORE >

08-05-2023

Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate

MORE >

25-04-2023, 17:59 CEST (Ad hoc press release)

Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance

MORE >

20-04-2023

Eckert & Ziegler Receives Manufacturing Authorization for GMP-grade Lutetium-177

MORE >

12-04-2023

Eckert & Ziegler Receives Environmental Approval for Jintan Radioisotope Site

MORE >

04-04-2023

Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

MORE >

30-03-2023

Eckert & Ziegler: Successful fiscal year 2022